Author

A. Nieto

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Carmona-Bayonas· 1 shared B. Sanchez-Laorden· 1 shared C. Lopez-Blau· 1 shared C. Ortega-Sabater· 1 shared D. Zaragoza Huesca· 1 shared F. Ayala de la Pena· 1 shared F. Bernardi· 1 shared F. Cabello-Torres· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Carmona-Bayonas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Microenvironmental Snail1 is a driver of immunosuppression in melanoma

M. Arumi-Planas, F. J. Rodriguez-Baena, F. Cabello-Torres, F. Gracia, C. Lopez-Blau, A. Nieto, B. Sanchez-Laorden

This study shows that Snail1 in the melanoma microenvironment promotes immunosuppression and tumor growth, suggesting it as a therapeutic target.

bioRxiv · Nov 23, 2022 · PreprintCancer Biology

Pro-tumor and prothrombotic activities of hepsin in colorectal cancer cells and suppression by venetoclax

M. C. Rodenas, J. Penas-Martinez, I. Pardo-Sanchez, D. Zaragoza Huesca, C. Ortega-Sabater, J. Pena-Garcia, S. Espin, G. Ricote, S. Montenegro, F. Ayala de la Pena, G. Luengo-Gil, A. Nieto, F. Garcia-Molina, V. Vicente, F. Bernardi, , I. Martinez-Martinez

This study shows hepsin promotes tumor aggressiveness and thrombosis in colorectal cancer, and venetoclax inhibits these effects by targeting hepsin.

bioRxiv · Oct 1, 2022 · PreprintCancer Biology